Abstract
Capecitabine (CAPE), a prodrug of 5-fluorouracil (5-FU), is widely adopted in clinical practice as a chemotherapeutic agent incorporated in the treatment of several malignancies such as colorectal and gastric cancer and is available on SUS. Although it has shown benefits in patient survival, its incidence of serious adverse events are very significant ,mostly gastrointestinal, dermatologi…